Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab First-Line and Second-Line in Advanced NSCLC
NCT00766246Phase 2Terminated
- Sponsor
- Pharmatech, Inc.
- Start
- Oct 2008
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Pharmatech, Inc.. Started Oct 2008; status: terminated.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00766246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00766246.